Physician profile
Ven Kottapalli
NPI 1144288408
$19,506.44
in general payments reported to CMS, 2019-2025
42 companies · $2,189 in 2025
The $2,189 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,108 · 2020: $1,446 · 2021: $1,435 · 2022: $1,820 · 2023: $9,284 · 2024: $2,225 · 2025: $2,189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $7,135 · Food and Beverage: $6,505 · Education: $57.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $7,135.44 |
| Food and Beverage | $6,504.77 |
| Education | $57.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $7,135.44 | 2023 | Evis Exera Lll Colonovideoscope |
| Abbvie INC. | $3,214.86 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $2,033.83 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,384.34 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $716.87 | 2020-2025 | Stelara, Simponi Aria, Simponi |
| Merck Sharp & Dohme LLC | $577.44 | 2019-2024 | Dificid |
| Qol Medical, LLC | $324.15 | 2020-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $320.37 | 2022-2025 | |
| Aimmune Therapeutics, INC. | $313.19 | 2023-2025 | Vowst, Zenpep |
| Evoke Pharma, INC. | $312.36 | 2021-2025 | Gimoti |
| Pfizer INC. | $291.80 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $253.50 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $252.31 | 2022-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $242.61 | 2019-2024 | Linzess |
| Nestle Healthcare Nutrition INC. | $237.98 | 2020-2023 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $229.64 | 2022-2025 | Ibsrela |
| Celltrion USA INC. | $203.46 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
| Allergan, INC. | $145.41 | 2019 | |
| Madrigal Pharmaceuticals | $138.94 | 2025 | Rezdiffra |
| Ferring Pharmaceuticals INC. | $138.35 | 2020-2025 | Rebyota |
| Daiichi Sankyo INC. | $136.35 | 2019-2023 | Injectafer |
| Gilead Sciences, INC. | $132.60 | 2021-2025 | |
| Lilly USA, LLC | $108.46 | 2024-2025 | Omvoh |
| Ambu INC. | $95.25 | 2020 | |
| Celgene Corporation | $87.48 | 2021-2024 | Zeposia |
| Novo Nordisk INC | $59.79 | 2023-2025 | Wegovy |
| Alnylam Pharmaceuticals INC. | $48.53 | 2020-2021 | |
| Pharmacosmos Therapeutics INC. | $46.50 | 2020-2021 | |
| Intercept Pharmaceuticals, INC. | $39.90 | 2020-2021 | |
| Shionogi INC | $39.59 | 2019 | |
| Sandoz INC. | $36.60 | 2023 | Hyrimoz |
| Ucb, INC. | $28.38 | 2020 | |
| Alfasigma USA, INC. | $28.16 | 2021 | |
| Medtronic, INC. | $21.05 | 2024 | Gi Genius |
| Axonics, INC. | $20.06 | 2024 | Axonics |
| Digestive Care, INC. | $19.75 | 2024 | Pertzye |
| Teva Pharmaceuticals USA, INC. | $19.18 | 2024 | Simlandi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.38 | 2023 | Cyltezo |
| Capsovision, INC. | $16.18 | 2023 | Capsocam Plus |
| Shire North American Group INC | $13.97 | 2019 | |
| Boston Scientific Corporation | $13.00 | 2022 | |
| Romark Laboratories, Lc | $11.43 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ven Kottapalli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.